Capstone Capital LLC Trims Holdings in Eli Lilly and Company (NYSE:LLY)

Capstone Capital LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 8.5% during the 1st quarter, Holdings Channel.com reports. The firm owned 312 shares of the company’s stock after selling 29 shares during the period. Eli Lilly and Company accounts for 0.2% of Capstone Capital LLC’s investment portfolio, making the stock its 19th largest holding. Capstone Capital LLC’s holdings in Eli Lilly and Company were worth $258,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Mascagni Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $43,000. Prudent Man Investment Management Inc. bought a new position in Eli Lilly and Company in the 4th quarter worth approximately $48,000. Highline Wealth Partners LLC boosted its stake in Eli Lilly and Company by 53.3% in the 1st quarter. Highline Wealth Partners LLC now owns 69 shares of the company’s stock worth $57,000 after purchasing an additional 24 shares during the period. Capital A Wealth Management LLC purchased a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $63,000. Finally, Bellwether Advisors LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $66,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $770.16 on Tuesday. The business’s 50 day moving average price is $780.81 and its 200-day moving average price is $800.36. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The company has a market cap of $729.91 billion, a P/E ratio of 62.67, a P/E/G ratio of 1.11 and a beta of 0.41. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm had revenue of $12.73 billion for the quarter, compared to analysts’ expectations of $12.77 billion. During the same period in the previous year, the firm earned $2.58 earnings per share. The firm’s quarterly revenue was up 45.2% compared to the same quarter last year. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.78%. Eli Lilly and Company’s dividend payout ratio is presently 48.82%.

Analyst Ratings Changes

LLY has been the subject of a number of research reports. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Erste Group Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. UBS Group cut their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. HSBC downgraded Eli Lilly and Company from a “buy” rating to a “reduce” rating and decreased their target price for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Finally, Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Saturday, June 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,011.79.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.